Corey Cutler, MD
Harvard/ Dana Farber Cancer Institute
Clinical Title: Novel Approaches For Prevention and Treatment of Chronic Graft vs. Host Disease in Allogeneic Stem Cell Transplantation
Description: Blood cancer patients often need bone marrow transplantation. The biggest risk is graft vs. host disease. This study hopes to demonstrate that a novel use of monoclonal antibody therapy may lead to the prevention and treatment of steroid-refractory chronic GVHD and increase a patient’s chance of survival.
Dr. Cutler’s innovative research is focused on development of novel methods of disease prevention and therapy for chronic graft-vs.-host disease in allogenic (donor) stem cell transplantation. Stem cell transplantation can be very effective for the treatment of certain types of cancer, such as leukemia. Some patients, however, experience graft-vs.-host disease, in which the newly transplanted immune system rejects the recipient, causing serious complications and even death. Dr. Cutler’s research aims are to prevent and effectively treat patients with the disease. To date, the study results are very promising.
Monoclonal antibody therapy has recently been explored in the treatment of steroid-refractory chronic GVHD and has been demonstrated to be effective. In this proposal, a novel approach to the prevention of chronic GVHD using the monoclonal antibody rituximab is presented, along with a clinical trial examining the role of the monoclonal antibody alemtuzumab as therapy for established steroid-refractory chronic GVHD. Chronic GVHD is the most important cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Novel uses of monoclonal antibody therapy may lead to the prevention and treatment of advanced GVHD.
The Gateway for Cancer Research is proud to support Dr. Corey Cutler in his groundbreaking work on a new approach for preventing and treating graft versus host disease, a potentially deadly complication faced by patients receiving stem cell transplants as treatment for certain types of cancer.
Accepting Patients? No« Back to Funded Clinical Trials
One American dies every 57 seconds from cancer.
These are loved ones, not statistics.
Demanding it all!
Funding innovative cancer research for
Treatments. Cures. Life.